St. Jude Medical Given New $61.00 Price Target at Barclays Capital (STJ)
Investment analysts at Barclays Capital raised their price target on shares of St. Jude Medical (NYSE:STJ) from $57.00 to $61.00 in a note issued to investors on Monday, AR Network reports. The firm currently has an “overweight” rating on the stock. Barclays Capital’s price target indicates a potential upside of 13.66% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of St. Jude Medical (NYSE:STJ) in a research note to investors on Wednesday, September 18th. They now have a $57.00 price target on the stock. Separately, analysts at Wells Fargo & Co. upgraded shares of St. Jude Medical (NYSE:STJ) from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, August 9th. Finally, analysts at TheStreet reiterated a “buy” rating on shares of St. Jude Medical (NYSE:STJ) in a research note to investors on Friday, July 19th.
Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $47.85.
Shares of St. Jude Medical (NYSE:STJ) traded down 0.07% on Monday, hitting $53.63. The stock had a trading volume of 566,645 shares. St. Jude Medical has a 1-year low of $30.25 and a 1-year high of $54.36. The stock has a 50-day moving average of $52.4 and a 200-day moving average of $46.4. The company has a market cap of $15.402 billion and a price-to-earnings ratio of 25.35.
St. Jude Medical (NYSE:STJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $0.96 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.94 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was down .5% on a year-over-year basis. Analysts expect that St. Jude Medical will post $3.72 EPS for the current fiscal year.
In other St. Jude Medical news, VP Mark Murphy sold 4,200 shares of St. Jude Medical stock on the open market in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $53.50, for a total value of $224,700.00. Following the sale, the vice president now directly owns 642 shares in the company, valued at approximately $34,347. The sale was disclosed in a filing with the SEC, which is available at this link.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.